ARWR
Arrowhead Pharmaceuticals Inc
64.20$
-0.9%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 54.8% | 38.0% | 56.7% | 50.9% | 61.0% | 56.3% | 72.1% | 68.6% | 68.6% | 73.2% | 81.1% | 79.1% | |
| 14.5% | 9.3% | 13.4% | 7.9% | 9.0% | 5.3% | 11.8% | 9.4% | 16.4% | 12.6% | 8.3% | 2.6% | |
| 52.7% | 35.2% | 54.8% | 49.4% | 59.7% | 54.5% | 69.7% | 65.2% | 66.4% | 57.1% | 78.7% | 75.8% | |
| 0.0% | – | – | – | 0.0% | 0.2% | 0.2% | 0.7% | 0.5% | 13.6% | 0.7% | 0.4% | |
| 43.8% | – | – | – | – | – | – | – | – | – | – | – | |
| 1.3% | 1.6% | 1.0% | 1.0% | 0.8% | 0.8% | 0.5% | 0.5% | 0.5% | 0.4% | 0.3% | 0.3% | |
| 62.5% | 72.3% | 48.1% | 61.6% | 83.2% | 94.5% | 56.5% | 62.3% | 63.7% | 64.9% | 73.6% | 77.9% | |
| 13.8% | 10.2% | 6.8% | 10.9% | 9.1% | 9.2% | 14.0% | 14.1% | 14.1% | 21.7% | 13.0% | 13.4% | |
| 1.4% | 0.5% | 0.6% | 0.7% | 0.6% | 0.8% | 4.6% | 3.4% | 3.4% | 3.0% | 2.1% | 1.9% | |
| 4.7% | 0.7% | 0.9% | 3.0% | 1.0% | 1.4% | 0.6% | 2.4% | 1.3% | 2.1% | 1.4% | 1.3% | |
| – | – | – | – | 34.5% | 40.2% | 13.3% | 14.5% | 15.5% | 10.2% | 37.1% | 39.0% | |
| 35.4% | 25.6% | 50.7% | 37.4% | 16.3% | 5.2% | 43.4% | 37.8% | 33.6% | 35.4% | 27.1% | 22.0% | |
| -134.0% | -185.0% | -134.4% | -164.6% | -142.6% | -177.4% | -90.8% | -116.1% | -117.5% | -99.5% | -76.2% | -91.1% | |
| 14.0% | 17.2% | 12.9% | 14.1% | 10.7% | 12.3% | 8.5% | 10.1% | 9.8% | 8.8% | 6.3% | 6.8% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.